Immupharma PLC Efforts in fight vs Covid-19 with Lupuzor; Ureka (8372M)
May 14 2020 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 8372M
Immupharma PLC
14 May 2020
RNS: FOR IMMEDIATE RELEASE 14 May 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
ImmuPharma's efforts in the fight against Covid-19 with
Lupuzor(TM) and Ureka
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company provides a
progress update on activities around Covid-19.
On 30 March 2020, ImmuPharma announced that it had expanded its
pipeline to include three new 'Anti-Infective' programs, one of
which was in 'Antivirals'. Investigation of the application of the
Ureka peptide technologies within this Antivirals program suggests
the potential to create effective anti-fusion peptides with the
goal to prevent virus entry into the host cells, which may lead to
novel peptide based antiviral therapies. Further exploratory work
continues on this program.
As part of an overall evaluation of how we might apply our
patented technologies to the fight against the Covid-19 epidemic,
within our 'Autoimmunity' therapy area, we have also been
considering the unique way that Lupuzor (TM) interacts with the
immune system and any potential application to Covid-19.
In this respect we note the results* of a recent study conducted
at Emory University Atlanta GA, suggesting that Covid-19
(SARS-COV-2) patients and systemic lupus erythematosus (SLE)
patients experiencing flares might share similar inflammatory
symptoms, underpinned by similar mechanisms (role of cytokines).
Lupuzor (TM) is a modulator of the immune response and an
anti-inflammatory agent, which has activity against SLE (lupus), an
autoimmune disease, as well as against other inflammatory diseases.
ImmuPharma, together with its US licencing partner, Avion
Pharmaceuticals, will be progressing Lupuzor (TM) into a new
optimised international Phase III trial this year in lupus
patients.
*"Critically ill SARS-CoV-2 patients display lupus-like
hallmarks of extraordinary B cell activation" -
https://doi.org/10.1101/2020.04.29.20083717 .
Given the findings of the Atlanta research group, we postulate
that Lupuzor (TM) may help to reduce or perhaps prevent the
occurrence of the cytokine storm seen in Covid-19 patients. Further
exploratory work is ongoing to assess Lupuzor's (TM) possible
potential and clinical program in Covid-19 patients.
Commenting on the announcement, Dimitri Dimitriou, CEO and Dr
Robert Zimmer, President & CSO of ImmuPharma said: " As the
Covid-19 pandemic has unfolded, ImmuPharma has been evaluating how
it can best contribute its expertise and resources to help in the
global response. Using our longstanding knowledge of peptide based
technology, provides us with a number of opportunities, to help
bring together a therapy that could be effective against the
inflammation that causes the serious complications of Covid-19. We
look forward to providing further updates when appropriate".
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 ("MAR").
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 8974
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 29 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase III trial for Lupuzor(TM) and commercialise in
the US. For additional information about ImmuPharma please visit
www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier)
code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDKKNBDKBKBQPD
(END) Dow Jones Newswires
May 14, 2020 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024